Evidence map›Paper›PMID 27554482›Full record

ArticleCancer research and treatment2017

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.

Seung Hoon Beom, Jisu Oh, Tae-Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong-Gon Moon, Sae-Won Han, Do-Youn Oh, Wonshik Han and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Seung Hoon BeomDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jisu OhDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Tae-Yong KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Kyung-Hun LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Yaewon YangDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Koung Jin SuhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Hyeong-Gon MoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sae-Won HanDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Do-Youn OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Wonshik HanDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Tae-You KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Dong-Young NohDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Seock-Ah ImDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLetrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcomes in Korean patients, although letrozole is widely used in practice. Therefore, this studywas conducted to affirm the efficacy and toxicities of letrozole in Korean patients. MATERIALS AND

methodsThis study retrospectively analyzed 84 HR-positive MBC patients who had been treated with letrozole from January 2001 to December 2012. Clinicopathological characteristics and treatment history were extracted from medicalrecords. All patients received 2.5 mg letrozole once a day until there were disease progressions or unacceptable toxicity. Progression-free survival (PFS) was the primary endpoint, and secondary endpoints were overall survival (OS), objective response rate (ORR), and toxicity.

resultsThe median age of the subjects was 59.3 years. Letrozole treatment resulted in a median PFS of 16.8 months (95% confidence interval [CI], 9.8 to 23.8) and a median OS of 56.4 months (95% CI, 38.1 to 74.7). The ORR was 36.9% for the 84 patients with measurable lesions. Multivariate analysis revealed symptomatic visceral disease (hazard ratio, 3.437; 95% CI, 1.576 to 7.495; p=0.002) and a disease-free interval ≤ 2 years (hazard ratio, 2.697; 95% CI, 1.262 to 5.762; p=0.010) were independently associated with shorter PFS. However, sensitivity to adjuvant hormone treatment was not related to PFS. Letrozole was generally well tolerated.

conclusionLetrozole showed considerable efficacy and tolerability as a first-line treatment in postmenopausal patients with HR-positive MBC.

Indexed as

PostmenopauseAdultAgedAged, 80 and overAntineoplastic AgentsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLetrozoleMiddle AgedAntineoplastic AgentsAromatase InhibitorsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesLetrozoleNitrilesReceptors, EstrogenReceptors, ProgesteroneTriazolesFirst-line treatmentHormone receptor-positiveKoreaLetrozoleMetastatic breast cancer

Identifiers

PMID27554482
PMCPMC5398408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.